Cagrilintide

Cagrilintide is a long-acting amylin analog studied for once-weekly appetite regulation and weight-management support.

Profile · 01

Overview

Cagrilintide is a long-acting acylated analog of amylin designed for once-weekly subcutaneous administration. It is not FDA-approved as a standalone therapy, though it is under advanced clinical development and has been studied both alone and in combination with semaglutide.

Human trials describe meaningful weight loss and a clear dose-response relationship, but gastrointestinal tolerability drives the need for slow titration. This page presents the weekly titration pattern from the source markdown as an educational research summary.

At a Glance

Goal
Support appetite regulation, satiety signaling, and weight-management outcomes through amylin-receptor activity
Categories
Weight LossAppetite RegulationMetabolic SupportAmylin Pathway
Synergistic
Semaglutide · Tirzepatide · L-Carnitine · Protein intake
Profile · 02

Protocol

Suggested weekly titration approach increasing dose every two weeks to improve tolerability.

Reconstitute
Add 3.0 mL bacteriostatic water to a 5 mg vial for about 1.67 mg/mL concentration
Typical weekly range
0.6-4.5 mg once weekly
Start
0.6 mg weekly for Weeks 1-2
Target
4.5 mg weekly by Weeks 7-16+
Frequency
Once weekly (subcutaneous)
Cycle Length
8-16 weeks; longer clinical-development protocols also exist
Timing
Use the same day each week and rotate injection sites
Route
Subcutaneous
Cycle
8-16+ weeks on, clinician-guided off periods

Inject once weekly and titrate gradually to improve gastrointestinal tolerability. At higher maintenance doses, injection volume becomes large enough that a standard insulin syringe may no longer be the ideal practical tool. Human evidence is stronger here than for many research peptides because formal clinical trial data exist.

Dose progression

Weeks 1-2
0.6 mg · 36 units (0.36 mL)
Weeks 3-4
1.2 mg · 72 units (0.72 mL)
Weeks 5-6
2.4 mg · 144 units (1.44 mL)
Weeks 7-16+
4.5 mg · 270 units (2.70 mL)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Science · 01

How Cagrilintide works.

Cagrilintide is a long-acting amylin analog with lipid modifications that extend half-life into the once-weekly range. It acts through amylin-receptor signaling in the central nervous system to reduce appetite and food intake.

Phase II and later combination-development data showed clinically meaningful weight loss, with stronger results at higher doses and in combination with semaglutide. Gastrointestinal side effects remain the dominant tolerability issue.

Science · 02

Effects

Observations from clinical or preclinical literature.

Clinical trials reported meaningful weight loss with a clear dose-response relationship
Supports appetite suppression and satiety signaling through amylin-pathway activity
Combination development with semaglutide suggests larger total weight-loss effects than either pathway alone
Most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, or constipation
Gradual titration helps improve tolerability
Mild injection-site irritation may occur
Science · 03

Caution

Not recommended during pregnancy or breastfeeding because safety data is insufficient
Use caution in severe gastrointestinal disease or gastroparesis
Use caution in people taking glucose-lowering medications because combined metabolic therapy may change tolerance
Consult a qualified healthcare provider before use if you have chronic medical conditions or endocrine disease

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

Electrolytes
Helpful when nausea or reduced food intake affects hydration and mineral balance.
Protein intake
Supports lean-mass preservation during weight loss.
B-complex vitamins
Support energy metabolism during caloric restriction.
Omega-3 fatty acids
Support broader metabolic health and inflammatory balance.
Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Pair with a balanced, protein-forward diet to reduce lean-mass loss during weight reduction
Use resistance training and aerobic activity to reinforce body-composition changes
Prioritize hydration and electrolyte intake, especially if gastrointestinal side effects appear
Monitor sleep and stress because both affect appetite regulation and adherence
Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

  1. Body weight and waist circumference - monitor weekly trends
  2. Appetite and satiety - track subjective changes to gauge effect
  3. Gastrointestinal symptoms - document nausea, vomiting, constipation, or diarrhea
  4. Injection-site reactions - note redness, swelling, or discomfort
Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

Fasting glucose and HbA1c
Track glycemic status during weight-management protocols.
Lipid panel
Useful for broader metabolic-health tracking.
CMP (Comprehensive Metabolic Panel)
Assesses liver, kidney, and electrolyte status.
CBC (Complete Blood Count)
General monitoring and baseline screening.
Thyroid panel
Useful when unexplained weight or energy issues overlap with thyroid status.
Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length
Vial size
Bac. water
Syringe
Vials
0 × 5 mg each…
Syringes
0
Bac. water
0 mL
Swabs
02 per syringe
Calculators · 02

Dose Calculator

Dose Calculator

Vial
Bac. water
Syringe
Dose
Concentration
0mg/mL
Volume per dose
0mL
…
Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

  1. Allow vial to reach room temperature for 15–20 minutes before reconstitution.
  2. Draw the chosen bacteriostatic water volume with a sterile syringe.
  3. Inject slowly down vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved (do not shake).
  5. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 30 days; discard any unused solution after 30 days.
Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean the vial stopper and injection site with alcohol and allow them to dry
Pinch a skinfold and insert the needle at 45-90 degrees into subcutaneous tissue
Do not aspirate for subcutaneous injections; inject slowly and steadily
Hold briefly before withdrawing the needle and rotate sites weekly
Discard used syringes immediately in a sharps container

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized
Store at room temp in dry, dark conditions; minimize moisture exposure.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.
Reference · 01

Notes

Use a new sterile syringe for each injection and dispose of it safely
Higher maintenance doses may require a more practical syringe setup than a standard insulin syringe
Track GI tolerability closely and slow escalation if needed
Cagrilintide is still an investigational compound and is not an FDA-approved standalone therapy
PepTribe is an educational platform. This information is for research and learning purposes only and is not medical advice.
Reference · 02

References

  1. The Lancet
    Phase 2 cagrilintide weight-management trial in overweight and obesity.
    https://pubmed.ncbi.nlm.nih.gov/34798060/
  2. Diabetes, Obesity and Metabolism
    Concomitant cagrilintide and semaglutide safety and pharmacodynamic study.
    https://pubmed.ncbi.nlm.nih.gov/33462919/
  3. NEJM / PubMed
    REDEFINE-era combination-development reporting for CagriSema.
    https://pubmed.ncbi.nlm.nih.gov/38587239/
  4. Molecular Metabolism
    Amylin pharmacology and clinical-potential review.
    https://pubmed.ncbi.nlm.nih.gov/26042198/
  5. CDC
    Subcutaneous injection route guidance.
    https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
  6. WHO (NCBI Bookshelf)
    Injection-safety guidance for subcutaneous administration.
    https://www.ncbi.nlm.nih.gov/books/NBK390474/
On this page